# Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy

> **NCT04770272** · PHASE2 · TERMINATED · sponsor: **Palleos Healthcare GmbH** · enrollment: 442 (actual)

## Conditions studied

- Triple-negative Breast Cancer

## Interventions

- **DRUG:** Atezolizumab 840 MG in 14 ML Injection
- **DRUG:** Atezolizumab 1200 MG in 20 ML Injection
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Biopsy Arm A
- **PROCEDURE:** Biopsy Arm B
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT04770272
- **Lead sponsor:** Palleos Healthcare GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-01
- **Primary completion:** 2023-07-06
- **Final completion:** 2024-10-02
- **Target enrollment:** 442 (ACTUAL)
- **Why stopped:** The trial stopped recruitment prematurely after a first planned interim analysis of the first 100 pCR results (given that a probability of less than 2.5% of meeting the primary endpoint was estimated).
- **Last updated:** 2026-01-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04770272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04770272, "Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04770272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*